Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil
NCT ID: NCT05034393
Last Updated: 2023-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
308 participants
OBSERVATIONAL
2022-02-04
2023-02-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metastatic Breast Cancer in Brazil: Characterization of Patients and Treatments
NCT02662868
Patterns of Care in Hormone-receptor Positive, Advanced Breast Cancer
NCT01277926
Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study
NCT05776147
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
NCT07217990
Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome
NCT06261918
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with de novo or recurrent HR-positive HER2-negative mBC
Patients diagnosed with de novo or recurrent HR-positive HER2-negative mBC from January 2018 to December 2020
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed hormone receptor-positive HER2-negative invasive breast cancer
* Hormone receptor-positive defined as 1% to 100% of tumor nuclei positive for Estrogen - - Receptor and/or Progesterone Receptor, as per ASCO/CAP Guideline 2020 - or Allred score of ≥3
* HER2-negative defined as IHC result is 0/1+ or 2+ with ISH negative as per ASCO/CAP Guideline 2018
* Diagnosed with de novo or recurrent metastatic breast cancer between January 2018 -and December 2020
* Public health system or private health system
Exclusion Criteria
* First-line treatment for mBC received through clinical trial
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Brazilian Breast Cancer Study Group (GBECAM)
UNKNOWN
Latin American Cooperative Oncology Group
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gustavo Werutsky
Role: PRINCIPAL_INVESTIGATOR
Latin American Cooperative Oncology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CINPAM - Centro Integrado de Pesquisa da Amazônia
Manaus, Amazonas, Brazil
CRIO - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
CLION - Clínica de Oncologia (Oncoclínicas)
Salvador, Estado de Bahia, Brazil
Hospital Sírio-Libanês DF
Brasília, Federal District, Brazil
IGESDF - Instituto de Gestão Estratégica em Saúde do Distrito Federal
Brasília, Federal District, Brazil
Instituto do Câncer Brasil - Unidade Pantanal
Corumbá, Mato Grosso do Sul, Brazil
Instituto do Câncer Brasil - Unidade Três Lagoas
Três Lagoas, Mato Grosso do Sul, Brazil
Instituto de Hematologia e Oncologia Curitiba (Oncoclínicas)
Curitiba, Paraná, Brazil
CPO - Centro Paraibano de Oncologia (Oncoclínicas)
João Pessoa, Paraíba, Brazil
HINJA - Hospital Jardim Armália
Volta Redonda, Rio de Janeiro, Brazil
CEPESG - Centro de Pesquisa e Educação da Serra Gaúcha
Caxias do Sul, Rio Grande do Sul, Brazil
HMV - Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil
CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Instituto do Câncer Brasil - Unidade Andradina
Andradina, São Paulo, Brazil
INCA - Instituto Nacional de Câncer
Rio de Janeiro, , Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LACOG 0221
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.